Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Massachusetts Medical Society
- Copyright date:
- Rights statement:
- © 2020 Massachusetts Medical Society. All rights reserved.
- This is the publisher's version of the article. The final version is available online from Massachusetts Medical Society at: https://doi.org/10.1056/NEJMoa2021436
Dexamethasone in hospitalized patients with Covid-19 — preliminary report
If you are the owner of this record, you can report an update to it here: Report update to this record